# US 2020/0390751 A1 · Antifungal agents with enhanced activity in acidic ph

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390751 A1
- Document ID: US20200390751A1
- Status: Published application
- Kind: A1
- Application number: 16/636,230
- Filed: 2018-07-31
- Published: 2020-12-17
- Earliest claimed: 2017-08-04
- Assignees: Scynexis, Inc.
- Applicants: Scynexis, Inc.
- Inventors: David A. ANGULO GONZALEZ
- Web page: https://patentgrep.com/patent/US20200390751A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 15/02: for disorders of the vagina
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.

## Claims

### Claim 1

A method of treating a fungal infection in a subject in need thereof, the method comprising administering to the subject a compound of Formula (I):
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O or H, H;
Re is C(O)NRfRg or a 6-membered ring heteroaryl group containing 1 or 2 nitrogen atoms wherein the heteroaryl group is optionally mono-substituted on a ring carbon with fluoro or chloro or on a ring nitrogen with oxygen;
Rf,Rg, R6 and R7 are each independently hydrogen or C1-C3 alkyl;
R8 is C1-C4 alkyl, C3-C4 cycloalkyl or C4-C5 cycloalkyl-alkyl;
R9 is methyl or ethyl; and
R8 and R9 are optionally taken together to form a 6-membered saturated ring containing 1 oxygen atom;
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 2 (depends on 1)

The method according to claim 1, wherein after administration of the compound or the pharmaceutically acceptable salt or hydrate thereof, the compound is present at the site of infection at a concentration effective to treat the yeast or mold infection.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound or the pharmaceutically acceptable salt or hydrate thereof is administered orally or intravenously.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound or the pharmaceutically acceptable salt or hydrate thereof is administered topically or via intra-lesional injection.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the fungal infection is selected from the group consisting of: vaginal yeast infection, fungal abscess, empyema, and an infection of the upper gastrointestinal tract.

### Claim 6

A method of treating a fungal infection in a subject in need thereof, the method comprising administering to the subject a compound of Formula (II):
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the pH is between about 4 and about 6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the pH is about 5 or lower.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the pH is about 4.5 or lower.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the fungal infection is caused by Candida spp.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the fungal infection is vulvovaginal candidiasis.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the fungal infection is recurrent vulvovaginal candidiasis.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein the subject is a human.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the concentration effective to treat the yeast or mold infection is lower than a concentration of the compound that would be required to treat a yeast or mold infection occurring at a pH of about 7 or higher.

### Claim 15

A method of preventing a fungal infection in a subject, the method comprising administering to the subject a compound of Formula (I):
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O or H, H;
Re is C(O)NRfRg or a 6-membered ring heteroaryl group containing 1 or 2 nitrogen atoms wherein the heteroaryl group is optionally mono-substituted on a ring carbon with fluoro or chloro or on a ring nitrogen with oxygen;
Rf, Rg, R6 and R7 are each independently hydrogen or C1-C3 alkyl;
R8 is C1-C4 alkyl, C3-C4 cycloalkyl or C4-C5 cycloalkyl-alkyl;
R9 is methyl or ethyl; and
R8 and R9 are optionally taken together to form a 6-membered saturated ring containing 1 oxygen atom;
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 16

A method of preventing a fungal infection in a subject, the method comprising administering to the subject a compound of Formula (II):
which is (1S,4aR,6aS,7R, 8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 17 (depends on 15, 16)

The method according to any one of claims 15-16, wherein after administration of the compound or the pharmaceutically acceptable salt or hydrate thereof, the compound is present at the site of infection at a concentration effective to prevent the occurrence of the yeast or mold infection.

### Claim 18 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the fungal infection is caused by Candida spp.

### Claim 19 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the fungal infection is vulvovaginal candidiasis.

### Claim 20 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the fungal infection is recurrent vulvovaginal candidiasis.

### Claim 21 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the pH is between about 4 and about 6.

### Claim 22 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the pH is about 5 or lower.

### Claim 23 (depends on 15, 16)

The method according to any one of claims 15-16, wherein the pH is about 4.5 or lower.

### Claim 24

A method of treating vulvovaginal candidiasis (VVC) infection in a subject in need thereof, the method comprising administering to the subject a compound of Formula (II):
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
wherein the VVC infection occurs in a condition or an anatomic area in which the pH is lower than about 5.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the compound of Formula (II) is administered orally.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the compound of Formula (II) is administered topically.

### Claim 27

A method of treating vulvovaginal candidiasis (VVC) infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable salt of a compound of Formula (II):
the compound being (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
wherein the VVC infection occurs in a condition or an anatomic area in which the pH is lower than about 5.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the pharmaceutically acceptable salt of the compound of Formula (II) is administered orally.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the pharmaceutically acceptable salt of the compound of Formula (II) is administered topically.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the citrate salt of the compound of Formula (II) is administered.

### Claim 31 (depends on 27)

The method according to claim 27, wherein the pharmaceutically acceptable salt of the compound of Formula (II) is administered orally in a tablet.

### Claim 32

A method of treating a fungal infection in a subject in need thereof, the method comprising administering to the subject a compound of Formula (IIa):
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 33

A method of preventing a fungal infection in a subject, the method comprising administering to the subject a compound of Formula (IIa):
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the fungal infection is a yeast or mold infection occurring in a condition or an anatomic area in which the pH is lower than about 7.

### Claim 34 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the pH is between about 4 and about 6.

### Claim 35 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the pH is about 5 or lower.

### Claim 36 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the pH is about 4.5 or lower.

### Claim 37 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the fungal infection is caused by Candida spp.

### Claim 38 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the fungal infection is vulvovaginal candidiasis.

### Claim 39 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the fungal infection is recurrent vulvovaginal candidiasis.

### Claim 40 (depends on 32, 33)

The method according to any one of claims 32-33, wherein the subject is a human.

### Claim 41 (depends on 32)

The method according to claim 32, wherein the concentration effective to treat the yeast or mold infection is lower than a concentration of the compound that would be required to treat a yeast or mold infection occurring at a pH of about 7 or higher.

### Claim 42

A method of treating vulvovaginal candidiasis (VVC) infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable salt of a compound of Formula (IIa):
the compound being (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10, 10a, 10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
wherein the VVC infection occurs in a condition or an anatomic area in which the pH is lower than about 5.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the pharmaceutically acceptable salt of the compound of Formula (IIa) is administered orally.

### Claim 44 (depends on 42)

The method according to claim 42, wherein the pharmaceutically acceptable salt of the compound of Formula (IIa) is administered topically.

### Claim 45 (depends on 42)

The method according to claim 42, wherein the citrate salt of the compound of Formula (IIa) is administered.

### Claim 46 (depends on 42)

The method according to claim 42, wherein the pharmaceutically acceptable salt of the compound of Formula (IIa) is administered orally in a tablet.
